Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Ready to take on
Aspergillus infections
Aspergillus infections
Liposomal Amphotericin B was chosen to help treat
Rashid's Aspergillus infection because it demonstrates:
Rashid's Aspergillus infection because it demonstrates:
Fungicidal activity against Aspergillus fumigatus13
Liposomal Amphotericin B has improved fungicidal
activity against the most clinically important yeast
and moulds vs. echinocandins and azoles.13–15
activity against the most clinically important yeast
and moulds vs. echinocandins and azoles.13–15
Liposomal Amphotericin B has a lower potential
for pharmacokinetic DDIs vs. azoles*16–18
for pharmacokinetic DDIs vs. azoles*16–18
Amphotericin B is not known to be a substrate nor an
inhibitor of the CYP450 enzyme system.16–18
inhibitor of the CYP450 enzyme system.16–18
Liposomal Amphotericin B has a well-
established tolerability and safety profile12**
established tolerability and safety profile12**
Very common adverse events associated with
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.12
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.12
*Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for a full list of DDIs. No specific interaction studies have been performed
with Liposomal Amphotericin B. However, recommendations in the prescribing information are based on the known DDI profile of amphotericin B and interactions
that may be of clinical significance.12 Drugs that are known to have pharmacodynamic interactions with amphotericin B may also interact with
Liposomal Amphotericin B.16–18 DDIs for amphotericin B are mostly related to nephrotoxicity and electrolyte disturbances, which may be augmented by
co-administered drugs with similar renal side effects. Resultant changes may reduce clearance or alter the efficacy/toxicity profile of co-administered drugs that
undergo renal elimination12,16–18 Regular monitoring of renal function is recommended in patients receiving Liposomal Amphotericin B in conjunction with any
nephrotoxic medications, and appropriate potassium supplementation may be required.12
with Liposomal Amphotericin B. However, recommendations in the prescribing information are based on the known DDI profile of amphotericin B and interactions
that may be of clinical significance.12 Drugs that are known to have pharmacodynamic interactions with amphotericin B may also interact with
Liposomal Amphotericin B.16–18 DDIs for amphotericin B are mostly related to nephrotoxicity and electrolyte disturbances, which may be augmented by
co-administered drugs with similar renal side effects. Resultant changes may reduce clearance or alter the efficacy/toxicity profile of co-administered drugs that
undergo renal elimination12,16–18 Regular monitoring of renal function is recommended in patients receiving Liposomal Amphotericin B in conjunction with any
nephrotoxic medications, and appropriate potassium supplementation may be required.12
**Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on its safety profile.
DAY 3
Liposomal Amphotericin B initiated
DAY 10
Treatment response
